Advertisement

FDA advisers endorse Pfizer’s COVID-19 vaccine for children ages 5 to 11

Middle school student Elise Robinson receives her first coronavirus vaccination on Wednesday,...
Middle school student Elise Robinson receives her first coronavirus vaccination on Wednesday, May 12, 2021, in Decatur, Ga. Hundreds of children, ages 12 to 15, received the Pfizer vaccine at the DeKalb Pediatric Center, just days after it was approved for use within their age group. (AP Photo/Ron Harris)(Ron Harris | AP)
Published: Oct. 26, 2021 at 4:21 PM EDT
Email This Link
Share on Pinterest
Share on LinkedIn

WASHINGTON (AP) — A panel of U.S. health advisers on Tuesday endorsed kid-size doses of Pfizer’s COVID-19 vaccine, moving the U.S. closer to beginning vaccinations in children ages 5 to 11.

A Food and Drug Administration advisory panel voted unanimously with one abstention that the vaccine’s benefits in preventing COVID-19 in that age group outweigh any potential risks — including a heart-related side effect that’s been very rare in teens and young adults who get a much higher dose.

The FDA isn’t bound by the panel’s recommendation and is expected to make its own decision within days.

If the FDA authorizes the kid-size doses, there’s still another step: Next week, the Centers for Disease Control and Prevention will have to decide whether to recommend the shots and which youngsters should get them.

While children are at lower risk of severe COVID-19 than older people, 5- to 11-year-olds still have faced substantial illness -- including over 8,300 hospitalizations reported, about a third requiring intensive care, and nearly 100 deaths.

The dose for young children is just one-third of the Pfizer shot already recommended for everyone 12 and older. Moderna also is studying its vaccine for young children.

Copyright 2021 The Associated Press. All rights reserved.